Table 3.
Median PFS and OS with HDIL-2 in mRCC at the 2-month landmark
| Median PFS (months) | Median OS (months) | |
|---|---|---|
| Overall | 6.9 | 34.2 |
| CR versus PR |
113.8 versus 11.0 (HR 0.17, CI 0.08–0.33) |
156.7 versus 37.8 (HR 0.22, CI 0.09–0.48) |
| CR versus SD |
113.8 versus 8.5 (HR 0.13, CI 0.06–0.22) |
156.7 versus 34.4 (HR 0.14, CI 0.06–0.29) |
| SD versus PD |
8.5 versus 2.6 (HR 0.13, CI 0.09–0.18) |
34.4 versus 12.2 (HR 0.33, CI 0.23–0.48) |
| OR versus (SD and PD) |
26.5 versus 4.9 (HR 0.25, CI 0.17–0.35) |
101.2 versus 24.1 (HR 0.26, CI 0.16–0.39) |
| (CR, PR, SD) versus PD |
10.4 versus 2.6 (HR 0.09, CI 0.07–0.13) |
53.9 versus 12.2 (HR 0.24, CI 0.17–0.34) |
| PR versus SD |
11.0 versus 8.5 (HR 0.74, CI 0.48–1.10) |
37.8 versus 34.4 (HR 0.66, CI 0.39–1.09) |
CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable or unknown, OR objective response, HR hazard ratio, and CI 95 % confidence interval